What is Novartis without Sandoz? Vas Narasimhan is 'patient' as new company takes form

Nicole DeFeudis

Editor

Vas Narasimhan is steadfast on his mission to reshape Novartis, culling a few programs last quarter and making the final arrangements to spin off generics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

What is Novartis without Sandoz? Vas Narasimhan is 'patient' as new company takes form

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA approves first drug to treat ultra-rare lipid storage disease

How AI can address ongoing challenges in the life sciences industry

What is No­var­tis with­out San­doz? Vas Narasimhan is 'pa­tien­t' as new com­pa­ny takes form

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

What is Novartis without Sandoz? Vas Narasimhan is 'patient' as new company takes form